Optimal anticoagulation duration of unfractionated and low molecular weight heparin in non-ST elevation acute coronary syndrome: A systematic review of the literature-Reference-Cited by-同舟云学术

Optimal anticoagulation duration of unfractionated and low molecular weight heparin in non-ST elevation acute coronary syndrome: A systematic review of the literature

Published:2014-12 Issue:2 Volume:177 Page:461-466
ISSN:0167-5273
Container-title:International Journal of Cardiology
language:en
Short-container-title:International Journal of Cardiology

Author:

Riaz Irbaz Bin,Asawaeer Majid,Riaz Haris,Gabriel Wendy M.,Tabash Ismail K.,Bilal Jawad,Alpert Joseph S.

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference27 articles.

1. Macrophage infiltration in acute coronary syndromes. Implications for plaque rupture;Moreno;Circulation,1994

2. Aspirin, heparin, or both to treat acute unstable angina;Theroux;N Engl J Med,1988

3. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group;Cohen;N Engl J Med,1997

4. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis;Oler;JAMA,1996

5. Rebound thrombin generation after heparin therapy in unstable angina. A randomized comparison between unfractionated and low-molecular-weight heparin;Bijsterveld;J Am Coll Cardiol,2002

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Periprocedural antithrombotic treatment in complex percutaneous coronary intervention;Journal of Cardiovascular Pharmacology;2021-12-07

2. In Vitro Thrombogenicity Testing of Biomaterials;Advanced Healthcare Materials;2019-10-15

3. Anticoagulants and Primary PCI;Primary Angioplasty;2018

4. Developing standards and test protocols for testing the hemocompatibility of biomaterials;Hemocompatibility of Biomaterials for Clinical Applications;2018

5. Thrombogenicity and hemocompatibility of biomaterials;Biointerphases;2016-06